These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 21784229)

  • 1. A fast track influenza virus vaccine produced in insect cells.
    Cox MM; Hashimoto Y
    J Invertebr Pathol; 2011 Jul; 107 Suppl():S31-41. PubMed ID: 21784229
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Protective immunity against influenza H5N1 virus challenge in mice by intranasal co-administration of baculovirus surface-displayed HA and recombinant CTB as an adjuvant.
    Prabakaran M; Velumani S; He F; Karuppannan AK; Geng GY; Yin LK; Kwang J
    Virology; 2008 Oct; 380(2):412-20. PubMed ID: 18786689
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Progress on baculovirus-derived influenza vaccines.
    Cox MM
    Curr Opin Mol Ther; 2008 Feb; 10(1):56-61. PubMed ID: 18228182
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Development of a novel recombinant influenza vaccine in insect cells.
    McPherson CE
    Biologicals; 2008 Nov; 36(6):350-3. PubMed ID: 18804387
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Baculovirus-expressed influenza vaccine. A novel technology for safe and expeditious vaccine production for human use.
    Safdar A; Cox MM
    Expert Opin Investig Drugs; 2007 Jul; 16(7):927-34. PubMed ID: 17594180
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunization against influenza A virus: comparison of conventional inactivated, live-attenuated and recombinant baculovirus produced purified hemagglutinin and neuraminidase vaccines in a murine model system.
    Brett IC; Johansson BE
    Virology; 2005 Sep; 339(2):273-80. PubMed ID: 15996702
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Influenza virus-like particle can accommodate multiple subtypes of hemagglutinin and protect from multiple influenza types and subtypes.
    Pushko P; Pearce MB; Ahmad A; Tretyakova I; Smith G; Belser JA; Tumpey TM
    Vaccine; 2011 Aug; 29(35):5911-8. PubMed ID: 21723354
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Influenza virus-like particles elicit broader immune responses than whole virion inactivated influenza virus or recombinant hemagglutinin.
    Bright RA; Carter DM; Daniluk S; Toapanta FR; Ahmad A; Gavrilov V; Massare M; Pushko P; Mytle N; Rowe T; Smith G; Ross TM
    Vaccine; 2007 May; 25(19):3871-8. PubMed ID: 17337102
    [TBL] [Abstract][Full Text] [Related]  

  • 9. FluBlok, a next generation influenza vaccine manufactured in insect cells.
    Cox MM; Hollister JR
    Biologicals; 2009 Jun; 37(3):182-9. PubMed ID: 19297194
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Insect larvae biofactories as a platform for influenza vaccine production.
    Gomez-Casado E; Gomez-Sebastian S; Núñez MC; Lasa-Covarrubias R; Martínez-Pulgarín S; Escribano JM
    Protein Expr Purif; 2011 Sep; 79(1):35-43. PubMed ID: 21421054
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of the safety, reactogenicity and immunogenicity of FluBlok trivalent recombinant baculovirus-expressed hemagglutinin influenza vaccine administered intramuscularly to healthy children aged 6-59 months.
    King JC; Cox MM; Reisinger K; Hedrick J; Graham I; Patriarca P
    Vaccine; 2009 Nov; 27(47):6589-94. PubMed ID: 19716456
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Baculovirus-produced influenza virus-like particles in mammalian cells protect mice from lethal influenza challenge.
    Tang XC; Lu HR; Ross TM
    Viral Immunol; 2011 Aug; 24(4):311-9. PubMed ID: 21830902
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dose-related safety and immunogenicity of a trivalent baculovirus-expressed influenza-virus hemagglutinin vaccine in elderly adults.
    Treanor JJ; Schiff GM; Couch RB; Cate TR; Brady RC; Hay CM; Wolff M; She D; Cox MM
    J Infect Dis; 2006 May; 193(9):1223-8. PubMed ID: 16586358
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hemagglutinin displayed baculovirus protects against highly pathogenic influenza.
    Tang XC; Lu HR; Ross TM
    Vaccine; 2010 Oct; 28(42):6821-31. PubMed ID: 20727393
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identification of HLA class II H5N1 hemagglutinin epitopes following subvirion influenza A (H5N1) vaccination.
    Zinckgraf JW; Sposato M; Zielinski V; Powell D; Treanor JJ; von Hofe E
    Vaccine; 2009 Aug; 27(39):5393-401. PubMed ID: 19596415
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Complete protection against a H5N2 avian influenza virus by a DNA vaccine expressing a fusion protein of H1N1 HA and M2e.
    Park KS; Seo YB; Lee JY; Im SJ; Seo SH; Song MS; Choi YK; Sung YC
    Vaccine; 2011 Jul; 29(33):5481-7. PubMed ID: 21664216
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of the safety, reactogenicity and immunogenicity of FluBlok® trivalent recombinant baculovirus-expressed hemagglutinin influenza vaccine administered intramuscularly to healthy adults 50-64 years of age.
    Baxter R; Patriarca PA; Ensor K; Izikson R; Goldenthal KL; Cox MM
    Vaccine; 2011 Mar; 29(12):2272-8. PubMed ID: 21277410
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Changing perspective on immunization against influenza.
    Johansson BE; Brett IC
    Vaccine; 2007 Apr; 25(16):3062-5. PubMed ID: 17276554
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An alternative method for preparation of pandemic influenza strain-specific antibody for vaccine potency determination.
    Schmeisser F; Vodeiko GM; Lugovtsev VY; Stout RR; Weir JP
    Vaccine; 2010 Mar; 28(12):2442-9. PubMed ID: 20074687
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Vaccines in development against avian influenza.
    Cox MM
    Minerva Med; 2007 Apr; 98(2):145-53. PubMed ID: 17519856
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.